Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.

doi:10.1080/10428190903040006

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.

Leukemia & lymphoma - 1 Aug 2009

Martínez-López Joaquin, Rivero Ana, Rapado Inmaculada, Montalbán Carlos, Paz-Carreira Jose, Canales Miguel, Martínez Rafael, Sánchez-Godoy Pedro, Fernández de Sevilla Alberto, Peñalver Francisco J, Gonzalez Marcos, Prieto Elena, Salar Antonio, Burgaleta Carmen, Queizán Jose A, Peñarrubia Maria J, Monteagudo Maria D, Cabrera Carmen, De la Serna Javier, Tomás José F

Abstract excerpt

The employment of current treatments based on chemotherapy and immunotherapy leads to inmunosuppression. The presence of mutations or polymorphisms in genes related to immune system might involve an additional disadvantage. The aim of the present study was to analyze mannose-binding lectin (MBL-2 gene) mutations and their association with severe infections and event-free survival in patients diagnosed with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Cyclophosphamide

Share to Lymphoma, Follicular

Share to Lymphopenia

Share to Multicenter Studies as Topic

Share to Rituximab

Share to Vidarabine

Source

Open in PubMed

Identifiers

PMID: 19557622
DOI: 10.1080/10428190903040006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.PMID 19557622Read ↗

Mannose-binding lectin 2 polymorphisms do not influence frequency or type of infection in adults with chemotherapy induced neutropaenia.Semantic proximity Read ↗

Patients with indolent lymphomas are at high risk of infections - Experience from a German outpatient clinicSemantic proximity Read ↗

Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma.Semantic proximity Read ↗

Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.Semantic proximity Read ↗

FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy.Semantic proximity Read ↗

Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphomaSemantic proximity Read ↗

HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy.Semantic proximity Read ↗

FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.